世界の性欲減退障害治療市場 – 2030 年までの業界動向と予測

性欲減退障害治療市場の分析と規模

性欲減退障害（HSDD）は現在、成人女性の間で増加傾向にあり、自信のなさやパートナーとのつながりの少なさが特徴です。さらに、腎不全、肝疾患、ホルモン不均衡、糖尿病、薬物中毒、アルコール中毒などの症状も性欲減退障害の原因となります。働く女性の増加と多忙な仕事スケジュールにより、性欲減退状態になることが多く、HSDD治療の需要が高まっています。

データブリッジ市場調査は、2023年から2030年の予測期間における性欲減退障害治療市場の成長率を分析しています。性欲減退障害治療市場の予想CAGRは、上記の予測期間中に約4％になる傾向があります。市場は2022年に1億3,970万米ドルと評価され、2030年までに1億9,120万米ドルまで成長すると予想されています。市場価値、成長率、市場セグメント、地理的範囲、市場プレーヤー、市場シナリオなどの市場洞察に加えて、データブリッジ市場調査チームがまとめた市場レポートには、詳細な専門家分析、患者疫学、パイプライン分析、価格分析、規制枠組みも含まれています。

性欲減退障害治療市場の範囲とセグメンテーション

Market Definition

Hypoactive sexual desire disorder is the most common type of sexual dysfunction that majorly occurs in the adult females. It is the type of condition in which there is lack of sex interest for a stretch of six months and more because of menopause, hormonal changes and the adoption of bad habits. Many patients suffering from this disorder may show the symptoms of lack of confidence, stressed, alcohol use and other behavioural changes.

Hypoactive Sexual Desire Disorder Treatment Market Dynamics

Drivers

• Increasing Awareness of Healthcare Infrastructure

A significant factor inducing the growth rate of hypoactive sexual desire disorder treatment market is the increasing healthcare expenditure, which helps improve its infrastructure. Furthermore, several government organizations aim to improve the healthcare infrastructure by growing the funding, that will further influence the market dynamics.

• Growing Level of Stress

Many people are stressed these days with many factors such as confront in the workplace, improper work-life balance, anxiety, depression that can lower the sex drive. Stress and tension at the workfront leads to a bad impact on our personal lives and can thus lead to this disorder, Thus, this instigates the demand for the treatment methods. 

Opportunities

• Increasing Demand of Advanced Therapies

There are several therapies that are developed to help cure this disorder patients. Psychotherapy is recommended for patients who positively respond to counselling sessions with a sex therapist. Pharmacotherapy consists of buspirone and bupropion off-label treatment for HSDD in women suffering from low libido associated with anxiety and depression. Furthermore, testosterone transdermal patches are an off-label treatment in premenopausal and postmenopausal women with HSDD. Due to its multifunctional serotonin agonist, the US FDA approved Flibanserin for treating this condition in premenopausal women.

 Restraints/Challenges

• Risk of Side-Effects

The diverse side-effects associated with hypoactive sexual desire disorder treatment could restrict the growth of the market over a forecast period. Complications such as anxiety, headache disorder, lower back pain, and irritation are prominent with the use of hypoactive sexual desire disorder treatment.

• High Cost of Treatment

There are numerous treatment processes that involves a huge cost. This type of disorder also involves counselling sessions, which demands monthly visits that cost high. Numerous hormonal therapies that are somewhat necessary for fast recovery but get unaffordable to many patients because of its high cost are impeding the market's growth.

This hypoactive sexual desire disorder treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hypoactive sexual desire disorder treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Hypoactive Sexual Desire Disorder Treatment Market Scope

The hypoactive sexual desire disorder treatment market is segmented on the basis of treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment Type

• Therapy
• Buspirone
• Bupropion
• Testosterone
• Flibanserin
• Bremelanotide
• Cognitive Behavior Therapy
• Drugs
• Others

Route of Administration

• Oral
• Parenteral
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Hypoactive Sexual Desire Disorder Treatment Market Regional Analysis/Insights

The hypoactive sexual desire disorder treatment market is analyzed and market size insights and trends are provided by treatment type, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the hypoactive sexual desire disorder treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

アジア太平洋地域では、性欲減退障害および性機能低下障害の治療に対する性欲減退障害治療の需要増加により、予測期間を通じて性欲減退障害治療市場がプラス成長を遂げています。

北米は、人口が継続的に増加し、働く女性と男性のストレスの発生率が高まっているため、市場を支配しています。

レポートの国別セクションでは、市場の現在および将来の動向に影響を与える国内市場における個別の市場影響要因と規制の変更についても説明しています。また、国別データの予測分析を提供しながら、グローバルブランドの存在と入手可能性、地元および国内ブランドとの競争が激しいか少ないために直面​​する課題、国内関税と貿易ルートの影響も考慮されています。   

競争環境と世界的性欲減退障害治療市場シェア分析

性欲減退障害治療市場の競争状況は、競合他社ごとに詳細を提供します。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、世界的なプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性などがあります。提供されている上記のデータ ポイントは、性欲減退障害治療市場に関連する会社の焦点にのみ関連しています。

性欲減退障害治療市場で活動している主要企業は次のとおりです。

• スプラウト・ファーマシューティカルズ社（米国）
• Covis Pharma GmbH (米国)
• マイランNV（米国）
• テバ製薬工業株式会社（イスラエル）
• アムニール・ファーマシューティカルズLLC（米国）
• ザイダスグループ（インド）
• サン・ファーマシューティカル・インダストリーズ（インド）
• アッヴィ社（米国）
• EndoCeutics, Inc. (カナダ)
• S1バイオファーマ株式会社（米国）

SKU-59193